Eli Lilly's Retatrutide Shows Major Promise in T2D Trial

Eli Lilly's novel GIP, GLP-1R, and glucagon triple hormone receptor agonist, retatrutide, has shown remarkable results in its Phase III TRANSCEND-T2D-1 study. The trial demonstrated that retatrutide achieved significant A1C reductions, ranging from 1.7% to 2.0%, in patients with type 2 diabetes over a 40-week period.

Furthermore, retatrutide proved effective in weight management, with patients losing an average of up to 16.8% of their body weight. This considerable weight loss continued throughout the treatment duration. The investigational drug also positively impacted key cardiovascular risk factors, including improvements in non-HDL cholesterol, triglycerides, and systolic blood pressure.

Adverse events reported were comparable to existing incretin-based therapies, with nausea, diarrhea, and vomiting being the most common. Eli Lilly anticipates presenting detailed trial results in June 2026. Retatrutide has also met endpoints in a separate Phase III weight loss trial, indicating its broad potential.

GlobalData projects a potential approval for retatrutide in 2027, forecasting substantial sales. This development places Eli Lilly in a competitive landscape with rivals like Novo Nordisk, which already has an approved oral GLP-1RA. The pharmaceutical giant also awaits a decision on its oral GLP-1RA, orforglipron.